塞力斯医疗科技集团股份有限公司 （二）出席董事会各专门委员会、独立董事专门会议工作情况 2024 年度独立董事述职报告 本人姚江，作为塞力斯医疗科技集团股份有限公司（以下简称"公司"）的 独立董事，我严格按照《中华人民共和国公司法》《上市公司治理准则》《上海 证券交易所上市公司自律监管指引第1号——规范运作》《上市公司独立董事管 理办法》等法律法规及《公司章程》《独立董事工作制度》的相关规定，在2024 年度工作中，勤勉、尽责、忠实履行职务，积极出席相关会议，认真审议董事会 的各项议案并对相关事项发表独立意见，维护了公司和股东，特别是中小股东的 合法权益。我已于2024年4月26日离任，现将我任职内履行职责情况汇报如下： 一、独立董事的基本情况 姚江，中国国籍，1967 年 8 月出生，中共党员，硕士研究生学历，金融类 经济师，高级经济师，注册风险管理师。曾参与筹建长江证券有限责任公司，先 后在营业部、发行部、基金部、投资银行部、资金部等核心业务岗位任经理；曾 在中国人民银行武汉分行（国家外汇管理局武汉分局）综合管理处、进出口核销 处、国际收支处等岗位从事监管工作；2016 年 5 月至 2017 年 8 月 ...

Financial Performance - The net profit attributable to shareholders of the listed company for 2024 is negative, leading to no cash dividends or capital reserve transfers for the year[6]. - The company's operating revenue for 2024 was approximately ¥1.81 billion, a decrease of 9.74% compared to ¥2.01 billion in 2023[26]. - The net profit attributable to shareholders for 2024 was approximately -¥209.24 million, representing a decline of 31.95% from -¥158.57 million in 2023[26]. - The cash flow from operating activities for 2024 was approximately ¥99.60 million, down 20.88% from ¥125.89 million in 2023[26]. - Total assets at the end of 2024 were approximately ¥2.83 billion, a decrease of 15.31% from ¥3.34 billion at the end of 2023[26]. - The net assets attributable to shareholders decreased by 22.84% to approximately ¥934.29 million in 2024 from ¥1.21 billion in 2023[26]. - The company reported a decrease in revenue from non-core business activities, with a total of approximately ¥1.81 billion in 2024, down 9.34% from ¥1.99 billion in 2023[26]. - The company recognized goodwill impairment losses totaling 25.22 million yuan across several subsidiaries, impacting overall financial performance[28]. - The company reported a net cash flow from operating activities of -27.15 million yuan in the first quarter of 2024, indicating cash flow challenges[33]. - Non-recurring losses amounted to 73.45 million yuan in 2024, compared to a loss of 11.71 million yuan in 2023[35]. Audit and Governance - The company has received a standard unqualified audit report from Zhongzheng Zhonghuan Accounting Firm[5]. - The board of directors has confirmed that all members attended the board meeting, ensuring accountability for the report's accuracy[4]. - The company has committed to maintaining the integrity and accuracy of its financial reports[5]. - The annual report is subject to approval at the 2024 annual general meeting of shareholders[6]. - The company has not reported any significant differences in governance compared to regulatory requirements[146]. - The company has not faced any major changes in competition or business independence issues from its controlling shareholders[146]. - The company is committed to optimizing governance and enhancing compliance awareness among its board and management team[170]. - The company implemented a registration management system for insider information to enhance transparency and protect shareholders' rights[146]. - The company held multiple shareholder meetings in 2024, including the first on January 15, where two proposals were approved, and the second on April 26, approving two additional proposals[146]. Strategic Development and Innovation - The company is focusing on the development of innovative technologies such as the TriVerity acute infection detection system and the LeviCell® cell separation technology[25]. - The company aims to expand its market presence through strategic partnerships and collaborations in the healthcare sector[25]. - The company is committed to enhancing its product offerings in molecular diagnostics and gut microbiome management[25]. - The company plans to continue its research and development efforts to improve diagnostic accuracy and patient outcomes[25]. - R&D investment in innovative technologies and software increased significantly, focusing on overseas technology commercialization and in vitro diagnostic reagent development[28]. - The company is actively transitioning from traditional IVD business to a light asset operation model, reducing fixed asset investments[43]. - The company is collaborating with Huawei to develop customized software solutions that meet hospitals' needs for flexible and low-cost solutions[45]. - The company is leveraging AI technology to optimize resource allocation and improve operational efficiency in healthcare institutions through various intelligent applications[66]. - The company aims to create a self-controlled, technology-leading innovative smart medical ecosystem by integrating AI and big data into its core business operations[64]. Market Trends and Opportunities - The aging population in China is projected to exceed 20% by 2030, driving increased demand for medical resources and healthcare spending[49]. - In 2024, the Chinese medical device market is expected to reach approximately 2.4 trillion yuan, with a compound annual growth rate (CAGR) of 16% by 2029[50]. - The SPD industry in China is projected to grow rapidly, with a market size of 64.2 billion yuan in 2024, of which the digital segment accounts for 19.3 billion yuan, reflecting a CAGR of over 20%[51]. - The public medical institutions' consumables management market is experiencing stable growth, driven by the need for cost control and the integration of AI and big data technologies[52]. - The global microbiome testing market is projected to grow at a CAGR of 22.5%, reaching over 965 million USD by 2029, driven by increasing health awareness and personalized health management needs[80]. Employee Management and Compensation - The total number of employees in the parent company is 239, while the main subsidiaries employ 1,007, resulting in a total of 1,246 employees[184]. - The company maintains a fair and competitive compensation policy, ensuring alignment with national regulations and market standards[185]. - Employee compensation consists of base salary, performance pay, and benefits, with a strong emphasis on linking pay to performance[186]. - The company has implemented a comprehensive training program to enhance employee skills and core competencies, supporting overall business objectives[187]. - The total remuneration for directors, supervisors, and senior management for the year 2024 is RMB 5.7971 million[156]. Regulatory Compliance and Risks - The company faced multiple regulatory warnings and criticisms from the Shanghai Stock Exchange and Hubei Securities Regulatory Bureau between 2022 and 2024, primarily related to information disclosure violations[161][162][164]. - On March 25, 2024, the company received a notice of investigation from the China Securities Regulatory Commission for suspected violations of information disclosure laws[165]. - The company received regulatory warnings from the Shanghai Stock Exchange due to overdue share repurchases, affecting the former chairman and other executives[166]. - The company was fined a total of 6 million for overdue share repurchases, with individual fines of 6.1 million for the former chairman and 1.3 million for the former general manager[169]. - The company is facing risks from intensified market competition and regulatory changes in the healthcare industry, necessitating adjustments in its business model[140]. Shareholder and Capital Management - The company has a cash dividend policy that aims for a minimum of 30% of the average distributable profit over the last three years to be distributed as cash dividends[189]. - For the fiscal year 2024, the company plans not to distribute cash dividends or convert capital reserves into share capital, pending shareholder approval[190]. - The company has not proposed a cash profit distribution plan despite having positive distributable profits, indicating a focus on reinvestment[191]. - The total amount repurchased and canceled over the last three fiscal years is RMB 171,222,135.75[192]. - The average annual net profit over the last three fiscal years is -RMB 180,138,286.54[192]. Board and Management Changes - The company experienced a change in its board of directors, with independent directors Liu Wei and Zhang Kaihua resigning due to term expiration, and new independent directors Zhang Zhaoguo and Shi Xianwang being elected[157]. - Independent director Yao Jiang submitted his resignation on April 26, 2024, and was replaced by Zhang Zhen, who also took over Yao's roles in the board's strategic and nomination committees[158]. - The fifth board and supervisory board elections were completed in August 2024, with new appointments including Wen Wei as chairman and Wang Zheng as general manager[159].

Financial Performance - The company reported a revenue of CNY 287.43 million for Q1 2025, a decrease of 40.75% compared to CNY 485.12 million in the same period last year[4]. - The net profit attributable to shareholders was a loss of CNY 14.32 million, down from a profit of CNY 3.16 million in the previous year, representing a decline of 553.66%[4]. - The company's cash flow from operating activities was negative CNY 50.63 million, compared to negative CNY 27.15 million in the same period last year[4]. - Total operating revenue for Q1 2025 was ¥287,429,208.68, a decrease of 40.7% compared to ¥485,121,921.87 in Q1 2024[22]. - Net profit for Q1 2025 was a loss of ¥11,765,669.24, compared to a profit of ¥14,336,396.76 in Q1 2024[23]. - Basic and diluted earnings per share for Q1 2025 were both -¥0.07, compared to ¥0.02 in Q1 2024[24]. Assets and Liabilities - The company’s total assets decreased by 19.74% to CNY 2.27 billion from CNY 2.83 billion at the end of the previous year[5]. - Total liabilities decreased to ¥1,330,358,087.98 in Q1 2025 from ¥1,868,026,362.40 in Q1 2024, a reduction of 28.7%[19]. - The total equity attributable to shareholders decreased to ¥920,025,332.15 in Q1 2025 from ¥934,292,086.63 in Q1 2024, a decline of 1.5%[19]. - The total cash and cash equivalents at the end of Q1 2025 were $165.72 million, slightly down from $169.65 million at the end of Q1 2024[28]. Cash Flow - The company’s cash flow statement for Q1 2025 is unaudited, indicating ongoing financial assessments[25]. - In Q1 2025, the cash inflow from operating activities was $355.44 million, a decrease of 37% compared to $565.54 million in Q1 2024[26]. - The net cash outflow from operating activities in Q1 2025 was $50.63 million, worsening from a net outflow of $27.15 million in Q1 2024[27]. - The net cash flow from investing activities in Q1 2025 was $44.30 million, a significant improvement from a net outflow of $3.65 million in Q1 2024[27]. - The cash inflow from financing activities in Q1 2025 was $42.51 million, compared to $38.80 million in Q1 2024, reflecting a 9% increase[28]. - The net cash outflow from financing activities in Q1 2025 was $35.42 million, an improvement from a net outflow of $63.39 million in Q1 2024[28]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 46,600[13]. - The largest shareholder, Saihai (Shanghai) Health Technology Co., Ltd., holds 21,642,540 shares, accounting for 11.33% of total shares[13]. - The top ten shareholders include various institutional and individual investors, with no significant changes in their holdings reported[15]. Research and Development - The company plans to increase R&D investment in smart hospital construction, IoT applications, and big data analysis platforms, which has led to a 43.54% increase in R&D expenses[10]. - The company's R&D expenses increased to ¥13,980,853.82 in Q1 2025, up 43.5% from ¥9,739,943.89 in Q1 2024[22]. - The company has ongoing research and development efforts, although specific new products or technologies were not detailed in the provided content[15]. Other Financial Metrics - The company reported a non-recurring gain of CNY 14.14 million, primarily from the disposal of non-current assets[8]. - Total expenses (selling, administrative, and financial) were CNY 74.59 million, a reduction of 5.11% compared to the same period last year[6]. - The weighted average return on equity was -1.68%, down from 0.28% in the same period last year, a decrease of 1.96 percentage points[5]. - The company reported an investment income of ¥11,670,780.29 in Q1 2025, compared to a loss of ¥3,391,747.83 in Q1 2024[23].

塞力斯医疗科技集团股份有限公司 2024 年度监事会工作报告 2024 年度，塞力斯医疗科技集团股份有限公司（以下简称"公司"）监事 会依据《中华人民共和国证券法》《中华人民共和国公司法》《上海证券交易所 股票上市规则》等法律法规及《公司章程》《监事会议事规则》等公司相关制度 规定，恪尽职守，积极履行法律、法规及股东大会赋予的职责和义务。 现将公司监事会 2024 年度工作情况报告如下： 一、2024 年监事会运行情况 公司监事会成员 3 名，均为公司关键岗位的员工，具有法律、财务、管理等 履行职责的专业能力。2024 年，公司监事会召开 8 次监事会会议，列席 12 次董 事会会议，参加 6 次股东大会。 2024 年公司监事会召开及表决情况如下： （一）2024 年 1 月 8 日，公司召开第四届监事会第二十二次会议审议通过 了《关于使用部分闲置募集资金暂时补充流动资金的议案》。 （二）2024 年 4 月 26 日，公司召开第四届监事会第二十三次会议审议通过 了如下议案： 1、《关于 2023 年度监事会工作报告的议案》 2、《关于公司 2023 年年度报告及其摘要的议案》 3、《关于公司 2023 年 ...

塞力斯医疗科技集团股份有限公司（以下简称"公司"）2024 年度财务报 表已经中审众环会计师事务所（特殊普通合伙）审计，并于 2025 年 4 月 27 日 出具了的无保留意见的审计报告。 塞力斯医疗科技集团股份有限公司 2024 年度财务决算报告 一、2024 年度主要会计数据及财务指标变动情况: 1、主要经营数据 单位：人民币 元 | 项 目 | 2024 年度 | 2023 年度 | 增减变动幅 | | --- | --- | --- | --- | | | | | 度(%) | | 营业收入 | 1,810,681,362.15 | 2,006,134,334.99 | -9.74 | | 营业成本 | 1,478,798,942.33 | 1,613,442,473.03 | -8.35 | | 销售费用 | 127,591,199.13 | 146,985,940.69 | -13.19 | | 管理费用 | 174,918,945.83 | 183,769,105.24 | -4.82 | | 研发费用 | 46,742,915.06 | 43,211,214.00 | 8.17 | | 财务费 ...

关于塞力斯医疗科技集团股份有限公司 非经营性资金占用及其他关联资金往来情况 汇总表专项审核报告 众环审字(2025) 0100974 号 质公用育优强国发达标额超展大赛干关 部情来给会议郑关业共见职古会资料智慧非 and and a the seat and a 100 昆布T090f07(@s0S) 平审视介 the state of the t a long the same 关于塞力斯医疗科技集团股份有限公司 奢性资金占用及其他关联资金往来情况汇总表 的专项审核报告 众环专字(2025) 0100974 号 塞力斯医疗科技集团股份有限公司全体股东: 我们接受委托,在审计了塞力斯医疗科技集团股份有限公司(以下简称"塞力医疗公司") 2024年 12月 31 日合并及公司的资产负债表,2024年度合并及公司的利润表、合并及公司 现流量表和合并及公司股东权益变动表以及财务报表附注的基础上,对后附的《上市公司 2024 年度非经营性资金占用及其他关联资金往来的情况汇总表》（以下简称"汇总表"）进 行了专项审核。按照中国证券监督管理委员会印发的《上市公司监管指引第 8 号 -- 上市公 司资金往来、对外担保的监管 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●本次会计政策变更是塞力斯医疗科技集团股份有限公司（以下简称"公司"） 根据财政部发布的《企业会计准则解释第 17 号》《企业会计准则解释第 18 号》 进行的相应变更，不会对公司财务状况、经营成果和现金流量产生重大影响，不 存在损害公司及全体股东利益的情形。 一、本次会计政策变更概述 （一）变更原因 | 证券代码：603716 | 证券简称：塞力医疗 | 公告编号：2025-037 | | --- | --- | --- | | 债券代码：113601 | 债券简称：塞力转债 | | 塞力斯医疗科技集团股份有限公司 关于会计政策变更的公告 本次变更前，公司执行财政部发布的《企业会计准则——基本准则》和各项 具体会计准则、企业会计准则应用指南、企业会计准则解释公告及其他相关规定。 （三）变更后采用的会计政策 本次会计政策变更后，公司将按照财政部发布的《企业会计准则解释第 17 号》《企业会计准则解释第 18 号》相关规定执行。其他未变更部分，仍按照财 政部前期发布 ...

塞力斯医疗科技集团股份有限公司 2024 年度董事会审计委员会履职报告 2024 年度，我们作为塞力斯医疗科技集团股份有限公司（以下简称"公 司"）董事会审计委员会委员，严格按照《公司法》《上市公司治理准则》 《上海证券交易所股票上市规则》等法律法规、规范性文件及《公司章程》 《董事会议事规则》及《董事会审计委员会实施细则》等相关规定和要求，本 着客观、公正、独立的原则，勤勉尽责，充分发挥公司审计委员会的职能，认 真履行了相应的职责和义务，现就 2024 年度工作情况向董事会报告如下： 一、审计委员会成员组成 公司第四届董事会审计委员会成员由独立董事刘炜女士、独立董事张开华 先生及董事温小明先生 3 名成员组成，由具备会计专业资格和经验的刘炜女士 担任审计委员会主任委员。公司于 2024 年 8 月 12 日完成换届选举工作，公司 第五届董事会审计委员会由独立董事张兆国先生、独立董事施先旺先生及董事 温小明先生 3 名成员组成，其中独立董事占比为三分之二，并由具备会计专业 资格和经验的张兆国先生担任审计委员会主任委员。审计委员会的成员资格和 构成均符合有关法律法规的规定。 二、审计委员会 2024 年度会议召 ...

塞力斯医疗科技集团股份有限公司 2024 年度董事会工作报告 塞力斯医疗科技集团股份有限公司（以下简称"公司"）作为数字化转型下 智慧医院建设一站式解决方案服务供应商，坚定不移以"SPD+IVD"双主业为智 慧医院生态拓展的驱动引擎，延伸布局独立第三方医学检验中心（ICL）、区域 医学检验中心（RMLC）共建、IVD 产品的研发制造、生命科学前沿技术的创新孵 化、创新医疗废物低碳分布式、本地化处理等，形成服务链条上的医疗器械及耗 材的全生命周期管理生态系统，进一步创新构建企业核心竞争力。 2024 年，公司董事会严格按照《中华人民共和国公司法》《中华人民共和 国证券法》《上海证券交易所股票上市规则》等法律法规及《公司章程》《董事 会议事规则》等公司相关制度规定和要求，规范运作，科学决策，积极推动公司 各项业务发展，维护公司和股东尤其是中小股东的合法权益。 | 会议届次 | | 召开日期 | | | 会议决议 | | --- | --- | --- | --- | --- | --- | | 第四届董事会第三十 | 2024 | 年 1 | 月 | 8 | 审议并一致通过了如下议案： | | 四次会议 | | ...

塞力斯医疗科技集团股份有限公司 董事会关于 2024 年独立董事独立性自查情况 专项意见 塞力斯医疗科技集团股份有限公司董事会 2025 年 4 月 29 日 经核查，独立董事张兆国、施先旺、张震均具备担任公司独立董事的任职资 格，上述人员未在公司担任除独立董事以外的任何职务，也未在公司主要股东公 司担任任何职务，与公司以及主要股东、实际控制人之间不存在利害关系或其他 可能妨碍其进行独立客观判断的关系。董事会认为公司独立董事符合《上市公司 独立董事管理办法》《上海证券交易所上市公司自律监管指引第 1 号——规范运 作》等法律法规中关于独立董事独立性的相关要求。 塞力斯医疗科技集团股份有限公司（以下简称"公司"）独立董事张兆国、 施先旺、张震于近日向董事会出具了《独立性情况自查表》，根据《上市公司独 立董事管理办法》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》 的有关规定及公司《独立董事工作制度》的相关要求，公司董事会就在任独立董 事的独立性情况进行评估并出具如下专项意见： ...